AXIM® Biotechnologies (OTCMKTS:AXIM) Files Patents For Facemask That Captures SARS-CoV-2 And For A Virus Binding Protein

Medical Marijuana Inc.’s (OTCMKTS:MJNA) investment firm AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has announced the filing of a provisional patent for a novel face mask that captures and deactivates the coronavirus, SARS-CoV-2 responsible for the COVID-19 pandemic.

AXIM’s facemask can capture and deactivate SARS-CoV-2

Stuart Titus, the CEO of Medical Marijuana, said that there has been an increase in demand for facemasks because of the pandemic, and the market is expected to hit $21.2 billion by 2026. Stuart said that AXIM’s novel face mask is revolutionary with use in almost every setting and will help the globe curb the spread of COVID-19. He added that they are proud to support AXIM, innovating a creative and essential solution in the fight against the pandemic.

It is important to note that the commercially available masks currently only filter aerosols containing viruses. But if the mask is moist, the virus can penetrate, thus increasing the infection risk. The AXIM mask has been designed for enhanced protection, whereby it captures the viruses in a mask filter layer before one can inhale them. AXIM employs an innovative set of reagents embedded in the mask layer to capture the virus instantly.

AXIM files patent for a recombinant virus binding protein

Recently, AXIM announced the filing of a provisional patent for a recombinant virus binding protein (VBP) for the coronavirus, SARS-CoV-2, and now it has commenced manufacturing of the VBP. According to studies, the spike protein of SARS-CoV-2 enters the host through locking of its receptor-binding domain to the human cell surface protein. Laboratory tests have shown that AXIM’s VBP can bind with the RBD spike protein.

Human cell surface proteins are vital in diagnostic testing of COVID-19 as they allow stimulation natural reaction to SAR-Cov-2 and help determine the efficacy of devices. However, the human cell surface proteins are expensive and are unstable molecules. But AXIM’S VBP has shown to be more than 10 times more stable and potent compared to VBP options currently available.

Related Posts

About The Author

Add Comment